Cristina Pellegrini

Prof. Dr. Cristina Pellegrini

orcid

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 March 2014 in Nature Genetics
Verified
Journal Article
Open access
PDF file
JSJianxin Shi
Jianxin Shi
XYXiaohong R. Yang
Xiaohong R. Yang
BBBari Ballew
Bari Ballew
MRMelissa Rotunno
Melissa Rotunno
DCDonato Calista
Donato Calista
MLMaria Teresa Landi
Maria Teresa Landi
Maria Teresa Landi and colleagues identify a rare missense variant in POT1 shared by five melanoma-prone families from Italy and associated with increased telomere length and telomere fragility. They also identify additional familial melanoma cases with rare missense variants in POT1 and find a significant excess of rare exonic POT1 variants in melanoma cases compared to controls, implicating POT1 variants in melanoma susceptibility. Although CDKN2A is the most frequent high-risk melanoma susceptibility gene, the underlying genetic factors for most melanoma-prone families remain unknown. Using whole-exome sequencing, we identified a rare variant that arose as a founder mutation in the telomere shelterin gene POT1 (chromosome 7, g.124493086C>T; p.Ser270Asn) in five unrelated melanoma-prone families from Romagna, Italy. Carriers of this variant had increased telomere lengths and numbers of fragile telomeres, suggesting that this variant perturbs telomere maintenance. Two additional rare POT1 variants were identified in all cases sequenced in two separate Italian families, one variant per family, yielding a frequency for POT1 variants comparable to that for CDKN2A mutations in this population. These variants were not found in public databases or in 2,038 genotyped Italian controls. We also identified two rare recurrent POT1 variants in US and French familial melanoma cases. Our findings suggest that POT1 is a major susceptibility gene for familial melanoma in several populations.

27 April 2020 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
MLMaria Teresa Landi
Maria Teresa Landi
DBD. Timothy Bishop
D. Timothy Bishop
Stuart MacGregorStuart MacGregor
Stuart MacGregor
MMMitchell J. Machiela
Mitchell J. Machiela
ASAlexander J. Stratigos
Alexander J. Stratigos
MLMatthew H. Law
Matthew H. Law

Verified
Journal Article
Open access
PDF file
CPCristina Pellegrini
Cristina Pellegrini
MMMaria Giovanna Maturo
Maria Giovanna Maturo
LNLucia Di Nardo
Lucia Di Nardo
VCValeria Ciciarelli
Valeria Ciciarelli
CGCarlota Gutiérrez García-Rodrigo
Carlota Gutiérrez García-Rodrigo
MFMaria Concetta Fargnoli
Maria Concetta Fargnoli
Basal cell carcinoma (BCC) is the most common human cancer and represents a growing public health care problem. Several tumor suppressor genes and proto-oncogenes have been implicated in BCC pathogenesis, including the key components of the Hedgehog pathway, PTCH1 and SMO, the TP53 tumor suppressor, and members of the RAS proto-oncogene family. Aberrant activation of the Hedgehog pathway represents the molecular driver in basal cell carcinoma pathogenesis, with the majority of BCCs carrying somatic point mutations, mainly ultraviolet (UV)-induced, and/or copy-loss of heterozygosis in the PTCH1 gene. Recent advances in sequencing technology allowed genome-scale approaches to mutation discovery, identifying new genes and pathways potentially involved in BCC carcinogenesis. Mutational and functional analysis suggested PTPN14 and LATS1, both effectors of the Hippo–YAP pathway, and MYCN as new BCC-associated genes. In addition, emerging reports identified frequent non-coding mutations within the regulatory promoter sequences of the TERT and DPH3-OXNAD1 genes. Thus, it is clear that a more complex genetic network of cancer-associated genes than previously hypothesized is involved in BCC carcinogenesis, with a potential impact on the development of new molecular targeted therapies. This article reviews established knowledge and new hypotheses regarding the molecular genetics of BCC pathogenesis.

1 March 2006 in Journal of Antimicrobial Chemotherapy
Verified
Journal Article
Open access
PDF file
GCGiuseppe Celenza
Giuseppe Celenza
CPCristina Pellegrini
Cristina Pellegrini
MCMarisa Caccamo
Marisa Caccamo
BSBernardetta Segatore
Bernardetta Segatore
GAGianfranco Amicosante
Gianfranco Amicosante
Mariagrazia PerilliMariagrazia Perilli
Mariagrazia Perilli
Objectives: To assess the prevalence and types of genes encoding extended-spectrum β-lactamases (ESBLs) in clinical isolates of Enterobacteriaceae, Pseudomonas aeruginosa and Acinetobacter spp. from Bolivia. Methods: A total of 642 clinical isolates were collected consecutively during a 4 month period (September to December 2004). Resistance or reduced susceptibility to cefotaxime and/or ceftazidime and/or aztreonam was assessed using double disc synergy tests using clavulanic acid, cefotaxime, ceftazidime and aztreonam to identify putative ESBL-producing isolates. The ESBL determinants were characterized by colony blot hybridization, PCR and DNA sequencing. Results: Of the 642 isolates, 220 (34.3%) showed resistance or reduced susceptibility to cefotaxime and/or ceftazidime and/or aztreonam, and 150 (23.4%) were putative ESBL producers. A total of 106 ESBL-producing isolates contained the blaCTX-M-2 gene, and 32 isolates had a novel allele, blaCTX-M-43. blaCTX-M alleles were detected in all P. aeruginosa and Acinetobacter spp. studied. In contrast, only 12 ESBL-producing isolates had blaPER-2, mainly Enterobacteriaceae, although it was also found in a strain of P. aeruginosa. Conclusions: This is the first study on ESBL-producing strains in Bolivia and it reveals a high prevalence of blaCTX-M genes. The PER-2 enzyme was less prevalent, but its gene was detected in several species, including P. aeruginosa, which is consistent with horizontal transfer.

23 March 2015 in Journal of the European Academy of Dermatology and Venereology
Verified
Journal Article
Closed access
PDF file
MFMaria Concetta Fargnoli
Maria Concetta Fargnoli
APA. Piccioni
A. Piccioni
LNLuca Neri
Luca Neri
STS. Tambone
S. Tambone
CPCristina Pellegrini
Cristina Pellegrini
KPKetty Peris
Ketty Peris

20 November 2019 in Journal of the European Academy of Dermatology and Venereology
Verified
Journal Article
Closed access
PDF file
LNLucia Di Nardo
Lucia Di Nardo
CPCristina Pellegrini
Cristina Pellegrini
ASAlessandro Di Stefani
Alessandro Di Stefani
LRLaura Del Regno
Laura Del Regno
PSPietro Sollena
Pietro Sollena
KPKetty Peris
Ketty Peris